Department of Neurosurgery, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
World Neurosurg. 2020 May;137:62-70. doi: 10.1016/j.wneu.2020.01.182. Epub 2020 Jan 31.
Moyamoya syndrome (MMS) in patients with sickle cell disease (SCD) accentuates the risk of recurrent strokes. Chronic transfusion therapy (CTT) is an excellent option for preventing recurrent strokes in most patients with SCD. In SCD with MMS, CTT may fail as a long-term solution. Cerebral revascularization, in the form of extracranial-intracranial bypass, has been shown to prevent recurrent strokes in this cohort. We review the evolution of this paradigm shift in the management of SCD-associated MMS. A systematic review, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol, was conducted. Our primary objectives were 1) to study the evolution of cerebral revascularization techniques in management of MMS in SCD and 2) to analyze the impact of neurosurgical intervention in this high-risk population. Four patients with SCD-associated MMS, who underwent indirect cerebral revascularization at our institute were retrospectively reviewed. A summary of 13 articles chronicling the advent and subsequent evolution of cerebral revascularization as a viable treatment strategy for stroke prevention in SCD-associated MMS is presented. The literature review suggests that early detection and surgical intervention (in addition to CTT) could significantly reduce stroke recurrence and improve neurocognitive outcome. Our short series of 4 patients also had a good outcome and no recurrence of strokes postoperatively. The literature emphasizes the use of a traditional standardized protocol for early identification (transcranial Dopplers, selective magnetic resonance angiography, and CTT). Early treatment and screening that involves early magnetic resonance angiography and referral to neurosurgery for revascularization may be considered for this high-risk population.
镰状细胞病(SCD)患者的烟雾病(MMS)会增加复发性中风的风险。慢性输血疗法(CTT)是预防大多数 SCD 患者复发性中风的绝佳选择。然而,在 MMS 合并 SCD 的患者中,CTT 可能无法长期解决问题。颅内外旁路搭桥术等脑血运重建已被证明可预防该队列的复发性中风。我们回顾了这一治疗模式转变在 SCD 相关 MMS 管理中的演变。我们按照系统评价和荟萃分析报告的首选条目进行了系统评价。我们的主要目标是 1)研究管理 SCD 相关 MMS 中脑血运重建技术的演变,2)分析神经外科干预对这一高危人群的影响。我们回顾性分析了在我们医院接受间接脑血运重建的 4 例 SCD 相关 MMS 患者。本文总结了 13 篇记录了脑血运重建作为 SCD 相关 MMS 预防中风的可行治疗策略的出现和后续演变的文章。文献回顾表明,早期检测和手术干预(除了 CTT 之外)可以显著降低中风复发率并改善神经认知结果。我们的 4 例患者的短期系列也取得了良好的结果,手术后没有中风复发。文献强调了早期识别(经颅多普勒、选择性磁共振血管造影和 CTT)的传统标准化方案的使用。对于这一高危人群,可以考虑早期磁共振血管造影和神经外科转诊进行血管重建的早期治疗和筛查。